Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
International Journal of Toxicology · 2025-12 · 44 (6) · 499-506
DOI: 10.1177/10915818251375348 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Toxicology, online erschienen am 09.09.2025. Verfasst von Jennifer Beck Pierson und 17 weiteren Autor:innen. Beteiligte Einrichtung: Health and Environmental Sciences Institute, Washington, DC, USA. Hauptthemen laut MEDLINE: Drug Development, Myocytes, Cardiac, Toxicity Tests. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FDA HHS, National Institutes of Health and Food and Drug Administration, Japan Agency for Medical Research and Development, Japan.
Abstract (Originalsprache)
Technological advances and the desire to reduce dependence on animal models have brought human-relevant models to the forefront of drug development. This paradigm shift is leveraging the advances in in vitro systems and new approach methodologies (NAMs), which was the focus of a workshop convened by the Health and Environmental Sciences Institute (HESI) in May 2024. Highlights included discussions on predicting cardiac failure modes and the utility of human-induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs), microfluidic systems like BioFlux™, and engineered heart tissues in enhancing early-stage drug safety assessments. Regulatory perspectives underscored the challenges and potential for integrating NAMs into submissions, advocating for standardized reporting and validation protocols. Case studies where NAMs offered superior predictivity compared to traditional methods are emerging and offer insights into a roadmap forward. However, there remains a need for collaboration among academia, industry, and regulatory bodies to ensure robust validation and adoption. These efforts aim to refine cardiovascular drug discovery, reduce attrition rates, and accelerate the transition toward more ethical and efficient preclinical testing paradigms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health and Environmental Sciences Institute, Washington, DC, USA.
- Vivodyne, Philadelphia, PA, USA.
- B2 Pathology Solutions, Raleigh-Durham, NC, USA.
- LabCorp Drug Development, Harrogate, UK.
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
- Bristol Myers Squibb, Lawrenceville, NJ, USA.
ORCID-Profile: Jennifer Beck Pierson, Anthony Bahinski, Sandy Eldridge, Yasunari Kanda, William B Mattes
Förderung
- FDA HHS
- National Institutes of Health and Food and Drug Administration
- Japan Agency for Medical Research and Development, Japan
Zitieren
APA
Pierson, J. B., Bahinski, A., Berridge, B., Bramham, D., Bourcier, T., Chaudhary, K. W., Eldridge, S., Kanda, Y., Mattes, W. B., Oliphant, J., Pang, L., Savtchenko, A., Siegel, J., Simpson, N., Tu, C., Wange, R., Wu, J. C., & Yang, X. (2025). Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development. International Journal of Toxicology, 44(6), 499-506. https://doi.org/10.1177/10915818251375348
Vancouver
Pierson JB, Bahinski A, Berridge B, Bramham D, Bourcier T, Chaudhary KW, et al. Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development. International Journal of Toxicology. 2025;44(6):499-506. doi:10.1177/10915818251375348
BibTeX
@article{Pierson2025,
author = {Pierson, Jennifer Beck and Bahinski, Anthony and Berridge, Brian and Bramham, Daniel and Bourcier, Todd and Chaudhary, Khuram W and Eldridge, Sandy and Kanda, Yasunari and Mattes, William B and Oliphant, Jessica and Pang, Li and Savtchenko, Alex and Siegel, Jeffery and Simpson, Natalie and Tu, Chengyi and Wange, Ronald and Wu, Joseph C and Yang, Xi},
title = {Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development},
journal = {International Journal of Toxicology},
year = {2025},
volume = {44},
number = {6},
pages = {499--506},
doi = {10.1177/10915818251375348}
}
EUVIMED